About: Revisión sobre las infecciones no bacterianas del aparato respiratorio: neumonías víricas

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Revisión sobre las infecciones no bacterianas del aparato respiratorio: neumonías víricas Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Revisión sobre las infecciones no bacterianas del aparato respiratorio: neumonías víricas
Creator	Aspa, Javier Rajas, Olga Galván, José
Source	Elsevier; PMC
abstract	Resumen Aunque las bacterias son los principales patógenos involucrados en la neumonía adquirida en la comunidad, algunos virus son responsables directos o en coinfección de un importante número de neumonías adquiridas en la comunidad. La clínica de estas neumonías puede ser muy similar, en el caso de los virus afectan más frecuentemente a la población infantil y geriátrica, con frecuencia no elevan la cifra de leucocitos, la fiebre es inconstante y frecuentemente se acompañan de síntomas de vías respiratorias altas. Característicamente no elevan la procalcitonina. Durante años el diagnóstico ha recaído en cultivos celulares y en detección de antígenos; desde la incorporación en la clínica de la PCR, la identificación de estos patógenos ha aumentado, descubriéndose nuevos microorganismos como el bocavirus. En general, el virus influenza A y el virus respiratorio sincitial siguen siendo los principales virus implicados. Sin embargo, la irrupción en los últimos años de epidemias con alta letalidad de coronavirus y de zoonosis de virus influenza hace que sea necesario mostrarse alerta ante estos nuevos patógenos emergentes. Los inhibidores de la neuraminidasa para neumonías víricas han demostrado disminuir la transmisión en casos expuestos y mejorar la evolución clínica en pacientes en Cuidados Intensivos; su uso en infecciones banales no está recomendado. La ribavirina ha sido utilizada en niños con infecciones por virus respiratorio sincitial, así como en inmunodeprimidos. Fuera de estos fármacos, ningún otro antiviral ha probado su eficacia. Las medidas de prevención con vacunación para virus influenza y con anticuerpos monoclonales para virus respiratorio sincitial podrían disminuir la incidencia de neumonía. Abstract Although bacteria are the main pathogens involved in community-acquired pneumonia, a significant number of community-acquired pneumonia are caused by viruses, either directly or as part of a co-infection. The clinical picture of these different pneumonias can be very similar, but viral infection is more common in the pediatric and geriatric populations, leukocytes are not generally elevated, fever is variable, and upper respiratory tract symptoms often occur; procalcitonin levels are not generally affected. For years, the diagnosis of viral pneumonia was based on cell culture and antigen detection, but since the introduction of polymerase chain reaction techniques in the clinical setting, identification of these pathogens has increased and new microorganisms such as human bocavirus have been discovered. In general, influenza virus type A and syncytial respiratory virus are still the main pathogens involved in this entity. However, in recent years, outbreaks of deadly coronavirus and zoonotic influenza virus have demonstrated the need for constant alert in the face of new emerging pathogens. Neuraminidase inhibitors for viral pneumonia have been shown to reduce transmission in cases of exposure and to improve the clinical progress of patients in intensive care; their use in common infections is not recommended. Ribavirin has been used in children with syncytial respiratory virus, and in immunosuppressed subjects. Apart from these drugs, no antiviral has been shown to be effective. Prevention with anti-influenza virus vaccination and with monoclonal antibodies, in the case of syncytial respiratory virus, may reduce the incidence of pneumonia.
has issue date	2015-11-30(xsd:dateTime)
bibo:doi	10.1016/j.arbres.2015.02.015
has license	els-covid
sha1sum (hex)	28f309f78ae68a7ad40bf2fb1b4cebece70c36e1
schema:url	https://doi.org/10.1016/j.arbres.2015.02.015
resource representing a document's title	Revisión sobre las infecciones no bacterianas del aparato respiratorio: neumonías víricas
has PubMed Central identifier	PMC7130696
schema:publication	Archivos de Bronconeumología
resource representing a document's body	covid:28f309f78ae68a7ad40bf2fb1b4cebece70c36e1#body_text
is schema:about of	named entity 'RIGHTS' named entity 'C O' named entity 'LONG' named entity 'USE' named entity 'THESE' named entity 'ARCH' named entity 'granted' named entity '2015' named entity 'CENTRE' named entity 'DATABASE' named entity '597' named entity 'COVID-19' named entity 'FORM' named entity 'UNRESTRICTED' named entity 'MEANS' named entity 'FREE' named entity 'ACTIVE' named entity 'ORIGINAL SOURCE' named entity '2015' named entity 'REPOSITORIES' named entity 'ADAS' named entity 'RESOURCE' named entity 'RESEARCH' named entity 'PERMISSIONS' named entity 'DEL' named entity 'R C' named entity 'FUNDED' named entity 'LAS' named entity 'COVID-19' named entity 'These' named entity 'virus' named entity 'mixto' named entity 'virus' named entity 'hace' named entity 'el 4' named entity 'adenovirus' named entity 'H5N1' named entity 'seguida' named entity 'Elsevier' named entity 'virus' named entity 'tabla' named entity 'PCR' named entity 'H1N1' named entity 'influenza' named entity 'H1N1' named entity 'adenovirus' named entity 'immunosuppressed' named entity 'varicella-zoster' named entity 'virus' named entity 'mantiene' named entity 'necrosis' named entity 'como' named entity 'el efecto' named entity 'tabla' named entity 'virus' named entity 'usan' named entity 'virus' named entity 'virus' named entity 'influenza' named entity 'zanamivir' named entity 'tabla' named entity 'vacuna' named entity 'como' named entity 'adenovirus' named entity 'como' named entity 'H5N1' named entity 'fallo' named entity 'PCR' named entity 'virus' named entity 'virus' named entity 'adenovirus' named entity 'zanamivir' named entity 'virus' named entity 'antiviral' named entity 'el mundo' named entity 'virus' named entity 'influenza' named entity 'virus' named entity 'Chlamydophila' named entity 'el mundo' named entity 'virus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software